Drugs / Inactivated convalescent plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04385186 | Jun → Nov 2020 | COVID-19 | National Blood Center Foundation, Hemolife | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated convalescent plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04385186 ↗ |
| Route | Other | “with a 24-hour interval via transfusion” NCT04385186 ↗ |